Immix Biopharma, Inc. IMMX Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number?
- Immix Biopharma, Inc. (IMMX) reported share-based compensation arrangement by share-based payment award, options, outstanding, number of $5.34M in Q1 2026.
- How has Immix Biopharma, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number changed year-over-year?
- Immix Biopharma, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number increased by 30.4% year-over-year, from $4.09M to $5.34M.
- What is the long-term trend for Immix Biopharma, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number?
- Over 5 years (2020 to 2025), Immix Biopharma, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number has grown at a 78.3% compound annual growth rate (CAGR), from $291.98K to $5.26M.